CD274 and glioblastoma: Against this background and to overcome the above-mentioned shortcomings, we have investigated the ability of targeted-PET imaging to measure PD-L1 expression quantitively in preclinical GBM models, providing more evidence for this approach to be translated into clinical trials for patient stratification.